Document is current
Any future updates will be listed below
-
Authors
Wang, Hua
Fu, Bi-bo
Wuxiao, Zhi-jun
Li, Ya-jun
Huang, Li
Ma, Jie
Zhai, Zhi-min https://orcid.org/0000-0003-4060-7600
Guo, Jing
Wu, Yuan-bin
Xu, Zhen-shu https://orcid.org/0000-0002-4803-3990
Feng, Jia
Zhou, Sheng-sheng
Chen, Ting-ting
Chen, Xing-gui
Li, Guo-wei
Liu, Ting-zhi
Huang, Hai-bin
Zheng, Run-hui
Li, Yong-hua
Tao, Hong-fang
Zi, Fu-ming
Wu, Fan https://orcid.org/0000-0002-4135-2227
Wang, Juan
Zeng, Hui https://orcid.org/0000-0002-4498-8888
Fu, Cai-bo
Gale, Robert Peter
Xia, Zhong-jun
Liang, Yang https://orcid.org/0000-0002-4226-9580
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Guangdong Province (2021A1515010093)
National Natural Science Foundation of China (81700148, 81873428)
Foundation for the National Institutes of Health
Ministry of Science and Technology of the People's Republic of China (84000-51200002, 84000-51200002)
Sun Yat-sen University (201603)
Guangdong Innovative and Entrepreneurial Research Team Program (2017ZT07S096)
Ministry of Science and Technology of the People's Republic of China
- License Information
-
More Information
Article History
Received: 15 May 2022
Revised: 29 July 2022
Accepted: 2 August 2022
First Online: 15 August 2022
Competing interests
: RPG is a consultant to NexImmune Inc. and Ananexa Pharma Ascentage Pharm Group, Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd. The other authors declare no competing interests.
: The study was approved by the Ethics Committee and Institutional Review Board of Sun Yat-Sen University Cancer Center (SZR2020-083) compliant with the principles of the Helsinki Declaration.
: The requirement for subject informed consent was waived because the study was retrospective and data were anonymized.
